Immunic IMUX
NASDAQ IMUX
$13.11 +0.35 (+2.74%)
At close: Sep 4, 2026 · 4:00 PM EDT

Immunic (IMUX) Preferred Stock Liabilities (2013)

Immunic (IMUX) posted Preferred Stock Liabilities of $1.4 million for Q4 2013.

Analysis

Immunic (IMUX) Preferred Stock Liabilities (2013) Analysis & Trends

Immunic has reported Preferred Stock Liabilities for 1 years, with the latest figure at $1.4 million in Q4 2013.

  • Quarterly Preferred Stock Liabilities changed N/A year-over-year to $1.4 million in Q4 2013, while the trailing twelve-month figure through Dec 2013 was $1.4 million (changed N/A YoY) and the FY2013 annual result came in at $1.4 million, changed N/A from the prior year.
  • Preferred Stock Liabilities held at $1.4 million in Q4 2013 per IMUX's latest filing.
  • Over five years, Preferred Stock Liabilities peaked at $1.4 million in Q4 2013 and troughed at $1.4 million in Q4 2013.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn -
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn -
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -
8 Royalty Pharma 28.45 Bn 27.61 Bn - -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -
10 Immunic 546.30 Mn 546.30 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2013 82.12 Mn